Immunogenicity of BNT162b2 vaccine booster against SARS-CoV-2 Delta and Omicron variants in nursing home residents: A prospective observational study in older adults aged from 68 to 98 years.

Lancet Reg Health Eur · 2022 · PMC9022478 · PMID 35469147

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Furthermore, all differences observed between pre-boost and three-month post-boost were statistically highly significant within both groups and the number of available samples three months after the booster dose was similar in both groups.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.